-- Scott Roberts
MONDAY, Oct. 31 (HealthDay News) -- Exparel (bupivacaine
liposome injectable suspension) has been approved by the U.S. Food
and Drug Administration to treat post-surgical pain, maker Pacira
Pharmaceuticals said Monday.
The product combines the long-acting anesthetic bupivacaine with
Pacira's DepoFoam delivery technology. A single dose can provide
relief for up to 72 hours and reduce the need for opioid
painkillers, the drug maker said in a news release.
Exparel was evaluated in 21 clinical studies, including more
than 1,300 participants. The most common side effects reported
included nausea, constipation and vomiting, Pacira said.
The company is based in Parsippany, N.J.
To learn more about
pain, visit Medline Plus.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.